A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

← catalyst calendar

NCT03958877 · readout in 274 d

Sponsored by Biogen (industry) · BIIB — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

152actual

Sites

Countries

Argentina, Australia, Belgium +19

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2019-10-18

actual

When the study began enrolling

Primary completion

2027-05-20

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-20

estimated

The whole study's end, after follow-up

First posted

2019-05-22

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-09-11

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Multiple Sclerosis, Relapsing-Remitting

Interventions

Drug: BIIB017 (peginterferon beta-1a) — also filed as PLEGRIDY
Drug: Interferon beta type 1a — also filed as Avonex

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Annualized Relapse Rate (ARR) at Week 48

measured Week 48

Part 2: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs Leading to Study Treatment Discontinuation

measured From Week 96 to Week 196

Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed